Fudan University: Liver Neoplasms trials

The registry lists 28 Liver Neoplasms studies with Fudan University as lead sponsor. 12 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 8Phase 3 6Phase 4 3No phase 11(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Effects of a Nurse-led TGA-based Pre-rehabilitation Planning on Perioperative Outcomes in Patients With Liver Cancer: Study and ProtocolEnrolling by invitationNCT07537205Not applicable
• Clinical Study on the Safety, Efficacy, and Exploration of Immune Mechanisms of a Combined Multimodal Tumor Therapy System for Hepatic MalignanciesRecruitingNCT07459309Not applicable
• HAIC Combined With Camrelizumab Plus Rivoceranib for Advanced Mixed Hepatocellular-cholangiocarcinoma (HCC-CCA)RecruitingNCT07105748Phase 2
• Postoperative Chemotherapy With/Without Radiotherapy and Immunotherapy for Colorectal Liver Metastases With High Risk of Locally RecurrenceRecruitingNCT06120127Phase 2
• Anatomical Resection VS. Nonanatomical Resection for Colorectal Liver Metastases With Gene Mutation or Right-sidednessNot yet recruitingNCT05881746Not applicable
• Effect of Hepatectomy on the Prognosis of Patients With Nasopharyngeal Carcinoma Liver MetastasesRecruitingNCT05771025Not applicable
• A Multicenter Registry Study on Stage III Hepatocellular Carcinoma in Unresectable CNLC Liver CancerNot yet recruitingNCT05660213
• Multimodal Deep Learning Signature for Evaluation of Response to Bevacizumab in Patient With Colorectal Cancer Liver MetastasisNot yet recruitingNCT05354674
• Cryoablation Combined with Sintilimab Plus Lenvatinib in Previously Treated Unresectable Liver Metastasis from Solid TumorsRecruitingNCT05098847Phase 2
• Lenvatinib Plus Sintilimab in Patients with Immune Checkpoint Inhibitor Previously Treated Advanced Liver CancerRecruitingNCT05010681Phase 2
• FOLFOXIRI Plus Cetuximab Versus FOLFOXIRI Plus Bevacizumab in Conversion Therapy of Right-sided Colon Cancer Liver MetastasesRecruitingNCT04832776Phase 2
• Conversion Therapy of RAS/BRAF Wild-Type Colorectal Cancer Patients With Initially Unresectable Liver MetastasesRecruitingNCT04687631Phase 3
• Multi-mode Ablation and Molecular Imaging Multi-omics Study for Digestive-Origin Malignant Liver TumorsActive, not recruitingNCT06588569Not applicable
• Multimodal Model for Efficacy Prediction Cetuximab in Colorectal Cancer Liver Metastasis PatientStatus unknownNCT05873972Not applicable
• Hepatic Arterial Infusion Chemotherapy Combined With Sintilimab and Regorafenib as Adjuvant Therapy for Colorectal Liver Metastasis Patients With a High Risk of Recurrent: a Single-arm, Phase II StudyStatus unknownNCT05753163Phase 2
• Camrelizumab Combined With Bevacizumab and HAIC in Patients With Metastatic Liver Cancer Who Failed Standard TherapyStatus unknownNCT05643417Phase 1
• Impact of Surgical Management for Relapse After Conversion Hepatectomy for Initially Unresectable Colorectal Liver MetastasisCompletedNCT05462470
• ALPPS Combined With Tislelizumab in Liver MalignancyStatus unknownNCT04996446Phase 2
• Preoperative Irinotecan Drug-eluting Beads for Patients With Unresectable Colorectal Liver MetastasisStatus unknownNCT04912258Phase 3
• Conversion Therapy of RAS/BRAF Wild-Type Right-sided Colon Cancer Patients With Initially Unresectable Liver MetastasesStatus unknownNCT04525326Phase 3
• Cetuximab Re-challenge for Colorectal Cancer Liver MetastasisStatus unknownNCT04509635Phase 3
• A Model for Predicting the Efficacy of Conversion Therapy for Patients With Colorectal Cancer Liver Metastases by the Detection of 5-hydroxymethylcytosine (5-hmC) in Plasma Cell-free DNAStatus unknownNCT03679039
• Study Comparing Radio Frequency Ablation Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLMStatus unknownNCT03127072Phase 4
• Safety of TACE With Oxaliplatin, Irinotecan and Raltitrexed for Refractory Colorectal Cancer Liver MetastasisStatus unknownNCT02631564
• Use of an Oxidized Regenerated Cellulose After Hepatic SurgeryStatus unknownNCT01436721Phase 2/3
• New Adjuvant Chemotherapy of Asymptomatic Resectable Primary Lesion With Unresectable Liver-limited MetastasesCompletedNCT01307878Phase 3
• Postoperative Folfox4 Only Versus Folfox4 Plus Transhepatic Arterial Chemotherapy (TAC) in the Treatment Unresectable Liver Metastasis of Colorectal CancerCompletedNCT00869271Phase 4
• Transhepatic Arterial Chemotherapy (TAC) Versus Transcatheter Arterial Chemoembolization (TACE) Plus Folfox4 as the Treatment of Unresectable Liver Metastasis of Colorectal CancerStatus unknownNCT00868569Phase 4